Printer Friendly

Securitas' board resolves on purchase of own series B shares.

NORDIC BUSINESS REPORT-June 6, 2019-Securitas' board resolves on purchase of own series B shares


Security services provider Securitas AB (STO:SECUB) announced on Wednesday the resolution by its board of directors, under the authorisation granted by the Annual General Meeting held on 6 May 2019, to repurchase the company's own series B shares on Nasdaq Stockholm.

The purpose of this acquisition is to ensure Securitas' undertakings in respect of share-related or share-based incentive programmes (other than delivery of shares to participants of incentive programmes), including covering social security costs.

This acquisition can commence on 5 June 2019 and will end no later than 1 May 2020 and will be administrated by Skandinaviska Enskilda Banken (SEB), which will take trading decisions independently of Securitas with regard to the timing of transactions.

A maximum of 1,000,000 series B shares may be purchased on one or more occasions. These acquisitions will be made at a price per share within the from time to time registered trading interval. Payment for the shares will be made in cash.

Currently, the total number of shares in Securitas amounts to 365,058,897, of which 17,142,600 are shares of series A and 347,916,297 are shares of series B. As on 5 June 2019, the company holds no own shares. In the event of a fully executed share repurchase, the company will own shares representing a maximum 0.3% of the issued shares in the company.

Securitas' services include specialised guarding and mobile services, monitoring and consulting and investigations.

((Comments on this story may be sent to

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Nordic Business Report
Date:Jun 6, 2019
Previous Article:Bavarian Nordic's ongoing phase 2 trial evaluating BN-Brachyury in chordoma shows positive results.
Next Article:Aspo announces final positive decision in Telko's administrative proceedings concerning surtax imposed by Customs.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters